BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36695555)

  • 1. Estrogen/Progesterone Receptor Loss, CTNNB1 and KRAS Mutations Are Associated With Local Recurrence or Distant Metastasis in Low-Grade Endometrial Endometrioid Carcinoma.
    Chibbar R; Foerstner S; Suresh J; Chibbar R; Piche A; Kundapur D; Kanthan R; Kundapur V; Lee CH; Agrawal A; Lai R
    Appl Immunohistochem Mol Morphol; 2023 Mar; 31(3):181-188. PubMed ID: 36695555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesonephric-like Endometrial Carcinoma: Results From Immunohistochemical Screening of 300 Endometrial Carcinomas and Carcinosarcomas for This Often Overlooked and Potentially Aggressive Entity.
    Mills AM; Jenkins TM; Howitt BE; Fan J; Ring KL; Cook I
    Am J Surg Pathol; 2022 Jul; 46(7):921-932. PubMed ID: 35195579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
    Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma.
    Costigan DC; Dong F; Nucci MR; Howitt BE
    Int J Gynecol Pathol; 2020 Mar; 39(2):119-127. PubMed ID: 30702464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors.
    Bartosch C; Monteiro-Reis S; Vieira R; Pereira A; Rodrigues M; Jerónimo C; Lopes JM
    PLoS One; 2015; 10(8):e0134969. PubMed ID: 26252518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.
    Liu Y; Patel L; Mills GB; Lu KH; Sood AK; Ding L; Kucherlapati R; Mardis ER; Levine DA; Shmulevich I; Broaddus RR; Zhang W
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
    Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
    Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of tissue microarray technique for the assessment of estrogen and progesterone receptors expression in endometrioid endometrial cancer--preliminary report].
    Gottwald L; Sek P; Kubiak R; Pasz-Walczak G; Piekarski J; Szwalski J; Suzin J; Tyliński W; Hendzel K; Jeziorski A
    Ginekol Pol; 2012 May; 83(5):342-6. PubMed ID: 22708330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
    Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
    J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Combined Morphologic and Molecular Approach to Retrospectively Identify KRAS-Mutated Mesonephric-like Adenocarcinomas of the Endometrium.
    Kolin DL; Costigan DC; Dong F; Nucci MR; Howitt BE
    Am J Surg Pathol; 2019 Mar; 43(3):389-398. PubMed ID: 30489318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FIGO Grade 3 Endometrioid Adenocarcinomas With Diffusely Aberrant β-Catenin Expression: An Aggressive Subset Resembling Cutaneous Pilomatrix Carcinomas.
    Weisman P; Park KJ; Xu J
    Int J Gynecol Pathol; 2022 Mar; 41(2):126-131. PubMed ID: 33811207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
    Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
    Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
    Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
    Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
    Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association.
    Kim G; Kurnit KC; Djordjevic B; Singh C; Munsell MF; Wang WL; Lazar AJ; Zhang W; Broaddus R
    Mod Pathol; 2018 Oct; 31(10):1553-1559. PubMed ID: 29795437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma.
    Haag JG; Wolsky RJ; Moroney MR; Sheren J; Sheeder J; Bitler BG; Corr BR
    Int J Gynecol Pathol; 2023 Jan; 42(1):43-53. PubMed ID: 35283443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer].
    Gottwald L; Kubiak R; Pasz-Walczak G; Sek P; Piekarski J; Szwalski J; Spych M; Chałubińska-Fendler J; Suzin J; Tyliński W; Jeziorski A
    Ginekol Pol; 2013 Feb; 84(2):95-101. PubMed ID: 23668054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.